Biosynthesis of mycobacterial arabinogalactan: identification of a novel alpha(1-3) arabinofuranosyltransferase
Birch, Helen; Alderwick, Luke; Bhatt, Apoorva; Rittmann, D; Krumbach, K; Singh, Albel; Bai, Y; Lowary, TL; Eggeling, L; Besra, Gurdyal

DOI: 10.1111/j.1365-2958.2008.06354.x

Citation for published version (Harvard):
Birch, H, Alderwick, L, Bhatt, A, Rittmann, D, Krumbach, K, Singh, A, Bai, Y, Lowary, TL, Eggeling, L & Besra, G 2008, 'Biosynthesis of mycobacterial arabinogalactan: identification of a novel alpha(1-3) arabinofuranosyltransferase', *Molecular Microbiology*, vol. 69, no. 5, pp. 1191-206. https://doi.org/10.1111/j.1365-2958.2008.06354.x

Link to publication on Research at Birmingham portal

General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

• Users may freely distribute the URL that is used to identify this publication.
• Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
• Users may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
• Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.
Biosynthesis of mycobacterial arabinogalactan: identification of a novel $\alpha$(1→3) arabinofuranosyltransferase

Helen L. Birch,1 Luke J. Alderwick,1 Apoorva Bhatt,1 Doris Rittmann,2 Karin Krumbach,2 Albela Singh,1 Yu Bai,3 Todd L. Lowary,3 Lothar Eggeling2 and Gurdyal S. Besra1*
1School of Biosciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.
2Institute for Biotechnology 1, Research Centre Juelich, D-52425 Juelich, Germany.
3Alberta Ingenuity Centre for Carbohydrate Science and Department of Chemistry, University of Alberta, AB, Canada T6G 2G2.

Summary

The cell wall mycolyl-arabinogalactan–peptidoglycan complex is essential in mycobacterial species, such as Mycobacterium tuberculosis and is the target of several antitubercular drugs. For instance, ethambutol targets arabinogalactan biosynthesis through inhibition of the arabinofuranosyltransferases Mt-EmbA and Mt-EmbB. A bioinformatics approach identified putative integral membrane proteins, MSMEG2785 in Mycobacterium smegmatis, Rv2673 in Mycobacterium tuberculosis and NCgl1822 in Corynebacterium glutamicum, with 10 predicted transmembrane domains and a glycosyltransferase motif (DDX), features that are common to the GT-C superfamily of glycosyltransferases. Deletion of M. smegmatis MSMEG2785 resulted in altered growth and glycosyl linkage analysis revealed the absence of AG $\alpha$(1→3)-linked arabinofuranosyl (Ara) residues. Complementation of the M. smegmatis deletion mutant was fully restored to a wild-type phenotype by MSMEG2785 and Rv2673, and as a result, we have now termed this previously uncharacterized open reading frame, arabinofuranosyltransferase C (AftC). Enzyme assays using the sugar donor $\beta$-D-arabinofuranosyl-1-monophosphoryl-decaprenol (DPA) and a newly synthesized linear $\alpha$(1→5)-linked Ara5 neoglycolipid acceptor together with chemical identification of products formed, clearly identified AftC as a branching $\alpha$(1→3) arabinofuranosyltransferase. This newly discovered glycosyltransferase sheds further light on the complexities of Mycobacterium cell wall biosynthesis, such as in M. tuberculosis and related species and represents a potential new drug target.

Introduction

Tuberculosis (TB) affects a third of the world population and causes 1.8 million fatalities annually (Dye, 2006). The spread of TB has been facilitated in recent years due to the susceptibility of HIV-infected individuals to Mycobacterium tuberculosis, the aetiological agent of TB (Paolo and Nosanchuk, 2004). The problem has also been compounded by the emergence of multidrug-resistant TB (MDR-TB) (Kaye and Frieden, 1996) and extensively drug-resistant (XDR)-TB strains (Shah et al., 2007). M. tuberculosis and other mycobacteria have a distinct cell wall which has a lipid-rich outer layer that is highly impermeable (Minnikin, 1982). One of the major components of this outer envelope are mycolic acids, long-chain $\alpha$-alkyl, $\beta$-hydroxy fatty acids that are essential for bacterial survival (Vilcheze et al., 2000; Portevin et al., 2004; Bhatt et al., 2005; Parish et al., 2007). These are found either esterified to the non-reducing termini of arabinogalactan (AG), or are present as trehalose esters, such as trehalose dimycolate (TDM) (Brennan and Nikaido, 1995; Dover et al., 2004).

A common feature of members of the Corynebacteriaceae is that they all possess this unusual cell wall architecture (McNeil et al., 1990; 1991; Besra et al., 1995). Apart from mycolic acids, the cell wall is dominated by a second macromolecule, an essential heteropolysaccharide termed AG, which is linked to both mycolic acids and peptidoglycan, forming the mycolyl-arabinogalactan–peptidoglycan (mAGP) complex (Daffé et al., 1990; McNeil et al., 1990; 1991; Besra et al., 1995). The formation of the arabinan domain ($\alpha$1→5, $\alpha$1→3 and $\beta$1→2 glycosyl linkages) of AG results from the subsequent addition of arabinofuranose (Ara) residues by a set of unique arabinofuranosyltransferases including, the Emb proteins of which three paralogues exist in Mycobacterium avium (Belanger et al., 1996) and M. tuberculosis (Telenti et al., 1997), AftA (Alderwick et al., 2006a) and AftB (Seidel et al., 2005). Enzyme architecture (McNeil et al., 1990; 1991; Besra et al., 1995). An interesting chemical feature of AG is the linkage of the non-reducing terminus of arabinogalactan (AG) results from the subsequent addition of arabinofuranose (Ara) residues by a set of unique arabinofuranosyltransferases including, the Emb proteins of which three paralogues exist in Mycobacterium avium (Belanger et al., 1996) and M. tuberculosis (Telenti et al., 1997), AftA (Alderwick et al., 2006a) and AftB (Seidel et al., 2005).
et al., 2007a). The lipid linked sugar donor β-D-arabinofuranosyl-1-monophosphorylecaprenol (DPA; Wolucka et al., 1994; Lee et al., 1995; 1997) serves as the substrate molecule for these complex membrane-bound glycosyltransferases.

The antituberculosis drug ethambutol (EMB) was shown to specifically inhibit AG biosynthesis (Takayama and Kilburn, 1989). The precise molecular target of EMB occupies the embCAB locus in M. tuberculosis (Telenti et al., 1997). To further define the role of EmbCAB proteins in cell wall arabinan biosynthesis, embA, embB and embC were individually inactivated in Mycobacterium smegmatis (Escuyer et al., 2001; Zhang et al., 2003). All three mutants were viable; however, the non-reducing terminal Ara6 motif which is the template for mycolylation in AG (McNeil et al., 1991) was altered in both the M. smegmatis (Ms)-embA and Ms-embB mutants (Escuyer et al., 2001), while Ms-embC was shown to be involved in the formation of the arabinan domains of lipoarabinomannan (LAM; Zhang et al., 2003). Attempts to obtain deletion mutants of embA (Amin et al., 2008) and embB in M. tuberculosis and embAB in M. smegmatis have proved unsuccessful (G.S. Besra, unpubl. results). In contrast, deletion of the single C. glutamicum (Cg)-emb orthologue and chemical analysis of the cell wall revealed a novel truncated AG structure possessing only terminal (t)-Araf residues with a corresponding loss of cell wall-bound mycolic acids (Alderwick et al., 2005). The presence of a novel enzyme responsible for ‘priming’ the galactan domain for further elaboration by Emb proteins led to the identification of AftA (Alderwick et al., 2006a). Recently, a retaining GT-C enzyme was identified, now termed AftB, which is responsible for the attachment of terminal β(1→2) Araf residues, and marks the ‘end-point’ for AG arabinan biosynthesis (Fig. 1) before decoration with mycolic acids (Seidel et al., 2007a).

It is clear that additional arabinofuranosyltransferases involved in AG and LAM biosynthesis still remain to be identified. Indeed, Liu and Mushegian (2003) identified 15 members of the GT-C superfamily residing in M. tuberculosis, representing candidates involved in the biosynthesis of cell wall-related glycans and lipoglycans (Liu and Mushegian, 2003). We have continued our earlier studies (Alderwick et al., 2006a,b; Seidel et al., 2007a) to identify genes required for the biosynthesis of the core structural elements of the mAGP complex by studying mutants of M. smegmatis and the orthologous genes and enzymes of M. tuberculosis and Corynebacterium glutamicum. Herein, we present MSMEG2785, Rv2673 and NCgl1822 as a new distinct arabinofuranosyltransferase of the GT-C superfamily, which is responsible for the transfer of Araf residues from DPA to the arabian domain to form α(1→3)-linked Araf residues, which result in the branched arabian domain distal to the non-reducing terminal Ara6 motif characteristic of mycobacterial AG.

**Fig. 1.** Biosynthetic pathway leading to arabinan formation in M. tuberculosis AG.

**Results**

**Genome comparison of the Rv2673 locus**

The arabinofuranosyltransferases EmbA, EmbB and EmbC are vital for M. tuberculosis and represent a target for the established drug EMB (Mikusova et al., 1995; Belanger et al., 1996; Telenti et al., 1997). Structural considerations of these proteins and a search for new drug targets resolved that more than 16 related proteins are
present in *M. tuberculosis*, possibly also acting as glycosyltransferases (Liu and Mushegian, 2003). In our systematic analysis of GT-C glycosyltransferases, focusing on those present in *M. tuberculosis* and *C. glutamicum*, we have previously identified the arabinofuranosyltransferases AftA (Alderwick *et al*. 2006a) and AftB (Seidel *et al*. 2007a), as well as several α-mannosyltransferases (Mishra *et al*. 2007; 2008). Each of these glycosyltransferases plays a specific yet decisive role in cell wall biosynthesis and assembly. In silico analysis of one of the putative glycosyltransferases of *M. tuberculosis*, Rv2673, highlighted that orthologues are present in a range of species belonging to the suborder *Corynebacterianeae*, including the families *Mycobacteriaceae*, *Corynebacteriaceae* and *Nocardiaceae* (Fig. 2A). Furthermore, the organization of the gene locus is largely retained. The adjacent genes are largely of unknown function. RibD encodes a bifunctional deaminase–reductase domain, followed by a gene product containing a hydrolase domain, which is however, absent in *Corynebacterium*, and downstream of Rv2673 a gene of unknown function is present. The wide distribution of Rv2673, its syntenic organization, and the fact that it is retained even in *M. leprae*, strongly indicates a fundamental function of its product. According to our experimental analysis (see below) we annotated this gene arabinofuranosyltransferase C (*aftC*).

*AftC* of *M. tuberculosis* is 433 amino acid residues long. It is a hydrophobic protein and is predicted to possess 10 transmembrane-spanning segments (Fig. 2B). However, in contrast to AftA, AftB or EmbC, it is characterized by the absence of a periplasmic carboxyterminal extension. The amino acid sequence among the *Corynebacterianeae* is very well conserved, and there are 43% identical residues shared by the *M. tuberculosis* and *C. glutamicum* proteins. The degree of conservation is particularly high in the loop regions, for instance between helixes 1 and 2, 3 and 4, or 6 and 7 (Fig. 2B). The fully conserved aspartyl (D) and glutamyl (E) residues, which we propose to be involved in catalysis or substrate binding, are located in the first extended loop region (Liu and Mushegian, 2003), as we have demonstrated for similarly located aspartyl (D) residues of Cg-Emb and AftB (Seidel *et al*. 2007a,b). Interestingly, the long transmembrane helix 8 is well conserved and it is within this region that there is a strong identity to a membrane protein of *Vibrio parahaemolyticus* (CpsG). Furthermore, this gene is located in a gene cluster involved in the biosynthesis of a capsular polysaccharide within this pathogen (Guvener and McCarter, 2003).

**Construction and growth of mutants**

In order to delete *aftC* and study for possible consequences we generated a null mutant of *M. smegmatis* mc²155 *MSMEG2785* (orthologue of Rv2673) using specialized transduction (Fig. 3A). In contrast to our *C. glutamicum* studies (see below) growth of *M. smegmatisΔaftC* in comparison to *M. smegmatis* was poor in liquid medium (Fig. 3B) and sensitive to the addition of Tween-80 on agar plates (> 0.005%). Complementation...
of *M. smegmatis*Δ*αftC* with either pMV261-Δ*αftC* or pMV261-*M. tuberculosis* (Mt)-*αftC* restored the mutant to a wild-type phenotype (Fig. 3B). On solid media *M. smegmatis*Δ*αftC* had a smooth and glossy appearance in comparison to the typical crenulated colony morphology found for wild-type *M. smegmatis* (Fig. 3C) and failed to stain as ‘acid-fast’ positive (data not shown). In addition, susceptibility of *M. smegmatis*Δ*αftC* to EMB and the hydrophobic antibiotics rifampicin and chloramphenicol was enhanced (minimal inhibitory concentration of 2, 100 and 10 mg ml⁻¹ for wild-type *M. smegmatis* in comparison to 0.4, 4 and 5 mg ml⁻¹ for *M. smegmatis*Δ*αftC* respectively), indicating increased permeability and that *M. smegmatis*Δ*αftC* had an altered cell wall. To study the function of the corynebacterial AftC the non-replicative plasmid pK19mobsacB was constructed. This was used to transform *C. glutamicum* to kanamycin resistance, indicating integration in its chromosome (Fig. S1A). Loss of vector was obtained by selection for sucrose-resistance yielding clones with *αftC* deleted. A PCR analysis with primer pairs P5 and P6 resulted in the expected fragment of 2160 bp for the wild-type and of 1065 bp for the deletion mutant, which was termed *C. glutamicumΔαftC*. Colonies of this mutant were more erose compared with the usual glossy appearance of the wild-type colony (data not shown). In contrast to *M. smegmatis*Δ*αftC*, the growth of the *C. glutamicumΔαftC* mutant on the salt medium CGXII possessed only a slightly reduced growth rate of 0.32 h⁻¹, whereas, that of the wild-type *C. glutamicum* was 0.39⁻¹ h⁻¹ (Fig. S1B).

**mAGP analyses from *M. smegmatis*, M. smegmatisΔαftC, M. smegmatisΔαftC pMV261-ΔαftC, M. smegmatisΔαftC pMV261-Mt-αftC, C. glutamicum and C. glutamicumΔαftC**

To study the function of mycobacterial αftC deletion, defatted cells were analysed qualitatively for AG esterified mycolic acids and cell wall-associated lipids from an equivalent starting amount of biomass for each strain due to differences in growth rate (Fig. 3B). As expected, *M. smegmatis* exhibited a typical profile of cell wall-bound α, α′ and epoxy-mycolic acid methyl esters (MAMEs), whereas, these products were drastically reduced in *M. smegmatis*Δ*αftC* (Fig. 4A). In addition, complementation of *M. smegmatis*Δ*αftC* with either pMV261-Δ*αftC* or pMV261-Mt-αftC (Fig. 4A), led to the restoration of normal ‘levels’ of cell wall-bound mycolic acids. Analysis of cell wall-associated lipids in several independent experiments highlighted an apparent increase in TDM for the αftC deletion mutant. This was confirmed quantitatively through [¹⁴C]acetate labelling of cultures and equal loading of radioactivity of extractable free lipids from *M. smegmatis*, *M. smegmatis*Δ*αftC* and the complemented *M. smegmatis*Δ*αftC* strain using plasmids pMV261-Δ*αftC* and pMV261-Mt-αftC (Fig. 4B). Typically, wild-type *M. smegmatis* synthesized 5250 cpm, whereas *M. smegmatis*Δ*αftC* afforded 14676 cpm of TDM after equivalent loading of radioactivity and quantitative analysis by phosphorimaging. Complementation of *M. smegmatis*Δ*αftC* with either pMV261-Δ*αftC* or pMV261-Mt-αftC restored the phenotype of the deletion mutant back to that of wild-type *M. smegmatis* (Fig. 4B). These results demonstrated that Ms-αftC and Mt-αftC are involved in a key aspect of arabinan biosynthesis, whereby deletion substantially perturbs tethering of mycolic acids to AG, which results in an increase in TDM production.

The cell wall core (mAGP) was prepared from *M. smegmatis* and *M. smegmatis*Δ*αftC* as described (Daffé et al., 1990; Besra et al., 1995; Alderwick et al., 2005) and the ratio of Ara to Gal in mAGP determined by gas chromatography (GC) analysis of alditol acetates (Daffé et al., 1990; Besra et al., 1995; Escuyer et al., 2001; Alderwick et al., 2005) (Fig. 5). The glycosyl composition was calculated based on a single rhamnosyl (Rha) residue per AG chain (McNeil et al., 1990). The glycosyl compositional analysis revealed a relative molar ratio of Rha : Ara : Gal of 1:71:31 and an Ara : Gal ratio of 2.3:1, which is in accord with previous data (Escuyer et al., 2001). The *M. smegmatis*Δ*αftC* mutant yielded AG with a significant reduction in Ara content concomitant with a relative increase in the amount of Gal. The *M. smegmatis*Δ*αftC* yielded an AG with an Rha : Ara : Gal ratio of 1:22:56 and an Ara : Gal ratio of 0.4:1. Complementation of *M. smegmatis*Δ*αftC* with either pMV261-Δ*αftC* or pMV261-Mt-αftC, restored the Rha : Ara : Gal ratio to that of wild-type *M. smegmatis*. Gas chromatography mass spectrometry (GC/MS) analysis of per-O-
In contrast to the mycobacterial \textit{aftC} deletion mutant, \textit{C. glutamicum}\textit{aftC} cells were analysed quantitatively for AG esterified corynomycolic acids due to similar growth rates between strains (Fig. S1B). Wild-type \textit{C. glutamicum} exhibited the known profile of corynomycolic acid methyl esters (CMAMEs, 35-345 cpm; Fig. S2), whereas, cell wall-bound CMAMEs were significantly reduced in \textit{C. glutamicum}\textit{aftC} (8023 cpm). The above data were reassuring as the qualitative (\textit{M. smegmatis}\textit{aftC}) and quantitative (\textit{C. glutamicum}\textit{aftC}) analyses were comparable in terms of a reduction in cell wall-bound mycolic acids (Fig. 4A and Fig. S2). Importantly, these results have also shown that Cg-\textit{aftC} is involved in a key aspect of arabinan biosynthesis, whereby deletion perturbs tethering of corynomycolic acids to AG. The GC/MS profiles of per-O-methylated alditol acetate derivatives of \textit{C. glutamicum} and \textit{C. glutamicum}\textit{aftC} are shown in Fig. S3 with \textit{C. glutamicum}\textit{aftC} also clearly devoid of 3,5-Araf branching residues.

In \textit{vitro} \textit{arabinofuranosyltransferase activity with extracts of \textit{M. smegmatis}, \textit{M. smegmatis}\textit{aftC} and \textit{complemented strains}}

Initial attempts to develop an \textit{in vitro} assay using either purified recombinant expressed AftC or \textit{E. coli} membranes expressing \textit{aftC}, have thus far proved unsuccessful, probably due to the hydrophobic nature of the protein. In an alternative approach, we assessed the capacity of membrane preparations from \textit{M. smegmatis}, \textit{M. smegmatis}\textit{aftC} and \textit{M. smegmatis}\textit{aftC} comple-

\section*{Fig. 4. Analysis of cell wall-associated lipids and bound MAMEs from \textit{M. smegmatis}, \textit{M. smegmatis}\textit{aftC}, \textit{M. smegmatis}\textit{aftC} pMV261-Ms-\textit{aftC} and \textit{M. smegmatis}\textit{aftC} pMV261-Mt-\textit{aftC}.}

A. Analysis of cell wall-bound MAMEs from \textit{M. smegmatis}, \textit{M. smegmatis}\textit{aftC}, \textit{M. smegmatis}\textit{aftC} pMV261-Ms-\textit{aftC} and \textit{M. smegmatis}\textit{aftC} pMV261-Mt-\textit{aftC}. The bound mycolic acids from an equivalent amount of freeze-dried cells (100 mg), which were initially de-lipidated using two consecutive extractions of CHCl\textsubscript{3}/CH\textsubscript{3}OH/H\textsubscript{2}O (10/10/3; v/v/v) at 50°C for 4 h, were released by the addition of tetra-butylammonium hydroxide at 100°C overnight, and methylated as described in the \textit{Experimental procedures}. An equivalent aliquot from each strain was subjected to TLC using silica gel plates (5725 silica gel 60F254, Merck), and developed in petroleum ether/acetone (95:5, v/v) and charred to reveal MAMEs and compared with known standards (Gande et al., 2004).

B. Quantitative analysis of extractable \textit{[14C]}-lipids from \textit{M. smegmatis}, \textit{M. smegmatis}\textit{aftC}, \textit{M. smegmatis}\textit{aftC} pMV261-Ms-\textit{aftC} and \textit{M. smegmatis}\textit{aftC} pMV261-Mt-\textit{aftC}. Lipids were extracted from cells by a series of organic washes as described in \textit{Experimental procedures} (Seidel et al., 2007a). An equivalent aliquot (50 000 cpm) from each strain was subjected to TLC using silica gel plates (5735 silica gel 60F254, Merck) developed in CHCl\textsubscript{3}/CH\textsubscript{3}OH/N\textsubscript{H}\textsubscript{2}O (80:20:2, v/v/v) and quantified using phosphorimaging and compared with known standards (Mikusova et al., 1995) after exposure to Kodak X-Omat film for 24 h.
Identification of a novel arabinofuranosyltransferase

M. smegmatis

M. smegmatisΔaftC

M. smegmatisΔaftC

M. smegmatisΔaftC

M. smegmatisΔaftC

Fig. 5. GC analysis of cell walls of M. smegmatis, M. smegmatisΔaftC, M. smegmatisΔaftC pMV261-Ms-aftC and M. smegmatisΔaftC pMV261-Mt-aftC. Samples of purified cell walls were hydrolysed with 2 M TFA, reduced, per-O-acetylated and analysed as described under Experimental procedures (Besra et al., 1995; Alderwick et al., 2005).

mented with pMV261-Mt-aftC to catalyse arabinofuranosyltransferase activity in the presence of exogenous synthetic acceptors (Lee et al., 1997; Seidel et al., 2007a).

We first assessed whether M. smegmatisΔaftC was deficient in α(1→5) and β(1→2) arabinofuranosyltransferase activity using an α-D-Araf(1→5)-α-D-Araf-O-(CH₃)₂CH₃ (Ara₅) synthetic acceptor (Lee et al., 1997) and DP[¹⁴C]A as a sugar donor based on an established assay format for determining α(1→5) and β(1→2) arabinofuranosyltransferase activities (Lee et al., 1998). TLC/autoradiographic analysis of the products which were only synthesized in the presence of Ara₅, when assayed with M. smegmatis membranes resulted in the formation of two products (A and B) (Fig. 7A and B). The enzymatic synthesis of products A and B are consistent with our previous studies using mycobacterial (Lee et al., 1997) and corynebacterial (Seidel et al., 2007a) membrane preparations resulting in trisaccharide products as a result of α(1→5) and β(1→2) Ara/linkages to the Ara₅ acceptor (Fig. 7A). Addition of EMB in several experiments, even at high concentrations of up to 1 mg ml⁻¹ to the reaction mixture, resulted in a decrease in only the in vitro synthesized α-D-[¹⁴C]Araf(1→5)-α-D-Araf(1→5)-α-D-Araf-O-(CH₃)₂CH₃ product A (Fig. 7A and B). Assays performed with membranes from M. smegmatisΔaftC and the pMV261-Ms-aftC complemented strain using the Ara₅ synthetic acceptor gave a similar profile to that of wild-type M. smegmatis (Fig. 7B). The data clearly show that the M. smegmatisΔaftC strain possesses comparable levels of EMB-sensitive α(1→5) and EMB-resistant β(1→2) arabinofuranosyltransferase activity.

The lack of α(1→3) arabinofuranosyltransferase activity in the previously reported Ara₅ and α-D-Araf(1→5)–α-D-Araf(1→5)–α-D-Araf-O-(CH₃)₂CH₃ (Ara₅) acceptor-based assays (Lee et al., 1997) required the development of an arabinofuranosyltransferase assay using the Ara₅-extended synthetic acceptor α-D-Araf(1→5)-α-D-Araf(1→5)-α-D-Araf(1→5)-α-D-Araf-O-(CH₃)₂NH₂ (Ara₅) (Supplementary experimental and Fig. S4) and DP[¹⁴C]A as a sugar donor (Lee et al., 1998). TLC/autoradiographic analysis of the products which are only synthesized in the presence of Ara₅, when assayed with M. smegmatis membranes resulted in the formation of a single product X (Fig. 8A) through the transfer of a single [¹⁴C]Araf residue, with a retardation factor (Rf) consistent with a synthetic Ara₅ acceptor (Appelmelk et al., 2008) standard (Fig. 8B). In addition, the synthesis of product X in overexpression studies was enhanced. Consistently from two independent membrane preparations and assays performed in triplicate from M. smegmatis pMV261-Mt-aftC produced product X (6453 cpm) in comparison to membranes from wild-type M. smegmatis (4289 cpm) in the above assays, demonstrating that AftC was functionally involved in the synthesis of product X. The inclusion of EMB in several experiments, even at high concentrations of up to 1 mg ml⁻¹ to the reaction mixture did not inhibit the synthesis of this in vitro synthesized [¹⁴C]Araf-Ara₅ acceptor was not extended via an EMB-sensitive α(1→5) arabinofuranosyltransferase. Interestingly, membranes prepared from the M. smegmatisΔaftC strain were unable to synthesize the in vitro product to the same level of activity that was observed with wild-type membranes prepared from M. smegmatis (Fig. 8A). This was to be expected, as our earlier in vivo and in vitro studies would have anticipated residual Ara₅ product formation, considering that M. smegmatisΔaftC possesses β(1→2) arabinofuranosyltransferase activity. Assays performed with...
membranes from the *M. smegmatisΔaftC* pMV261-Mt-aftC complemented strain, gave a similar profile to that of wild-type *M. smegmatis* (Fig. 8A).

To establish that the Ara5 acceptor is being utilized by two different arabinofuranosyltransferases, presumably establishing β(1→2) and α(1→3) linkages, assays similar to that used before were scaled up (see Experimental procedures) and product X extracted and purified through preparative TLC for each membrane preparation. GC (Sassaki *et al.*, 2005) and GC/MS (Alderwick *et al.*, 2005) analyses of the partially per-O-methylated, per-O-acetylated alditol acetate derivatives of product X in assays performed with *M. smegmatis* membranes revealed the addition of β(1→2) [Rt 11.75 min; m/z 129, 130, 161, 190] and α(1→3) [Rt 12.39 min; m/z 118, 129, 130, 190, 202, 233] linked Araf residues (Fig. 9A and B). Therefore, the product migrating below Ara5 and coincident with the Ara6 acceptor standard on TLC (Fig. 8A and B) is in fact a mixture of two products (Fig. 9B). The addition of β(1→2)-linked Araf residues can be attributed to the function of AftB. The presence of α(1→3)-linked Araf residues in this assay using an Araα acceptor clearly highlights the role of a novel arabinofuranosyltransferase(s) capable of functioning in an α(1→3) capacity. Importantly, the level of α(1→3) activity when the Araα acceptor is incubated with membranes prepared from *M. smegmatisΔaftC* is completely abolished (Fig. 9A). However, β(1→2) activity is clearly present in *M. smegmatisΔaftC* (Fig. 9A). In addition, *M. smegmatisΔaftC* complemented with pMV261-Mt-aftC restores α(1→3) arabinofuranosyltransferase activity to wild-type *M. smegmatis* (Fig. 9A). The results clearly establish both from in vivo and in vitro experiments that AftC catalyses the addition of an α(1→3)-Araf unit via an α(1→3) arabinofuranosyltransferase and that this enzyme is also resistant to EMB (Fig. 8A).

**Discussion**

The mAGP complex represents one of the most important cell wall components of the *Corynebacteriaceae* and is
essential for the viability of *M. tuberculosis* (Vilcheze et al., 2000; Pan et al., 2001; Gande et al., 2004; Mills et al., 2004). It is therefore not surprising that one of the most effective antimycobacterial drugs, EMB, targets its synthesis through inhibition of AG biosynthesis. However, the emergence of MDR-TB and XDR-TB has accelerated the need to discover new drug targets (Brennan and Nikaido, 1995). One of the strategies is to identify genes involved in AG biosynthesis. Based on this strategy we previously identified the presence of a new ‘priming’ enzyme, now termed AftA, which would link the initial Ara\(\_f\) unit with the C-5 OH of a \(\beta(1 \rightarrow 6)\) linked Gal\(\_f\) of a presynthesized galactan core (Alderwick et al., 2005), and more recently identified the AftB enzyme responsible for \(\beta(1 \rightarrow 2)\) Ara\(\_f\) residues.

The previously described Emb (Alderwick et al., 2005), AftA (Alderwick et al., 2006a) and AftB proteins (Seidel et al., 2007a) are distinct arabinofuranosyltransferases. Thus, despite some functional relationship, these glycosyltransferases have inherent specific features as evident from the insensitivity of AftA and AftB towards EMB, whereas the single Cg-Emb (Alderwick et al., 2005; Radmacher et al., 2005) and Mt-Emb proteins are sensitive towards EMB (Telenti et al., 1997; Belanger et al., 1996). The number of arabinofuranosyltransferases that are required for mycobacterial arabinan biosynthesis has been a matter of speculation to date depending on how the arabinan chains are assembled. The primary structure of AG (Besra et al., 1995; Daffé et al., 1990) would suggest at least five distinct arabinofuranosyltransferases are required for the complete formation of AG. Interestingly, *M. smegmatis* embA and embB mutants were found to possess reduced amounts of the non-reducing terminal disaccharide \(\beta-D-Ara\_f-(1 \rightarrow 2)-\alpha-D-Ara\_f\) and result in the removal of the dominant terminal non-reducing Ara\(\_s\) branched motif in the mutant being replaced by a linear Ara\(\_s\) motif (Escuyer et al., 2001). The authors of this study concluded that the *M. smegmatis* embA and embB mutants result in a lack of 3-arm branching off the main \(\alpha(1 \rightarrow 5)\)-arabinan chain proximal to the non-reducing and attachment site of mycolic acids in AG (Escuyer et al., 2001). Initially, it was proposed that the \(\beta-D-Ara\_f-(1 \rightarrow 2)-\alpha-D-Ara\_f\) disaccharide was assembled using EmbA and EmbB. However, the recent identification of AftB, the development of specific *in vitro* assays in combination with mutant strains, and recent structural studies have
fig. 8. arabinofuranosyltransferase activity utilizing an ara₅ acceptor and membranes prepared from M. smegmatis, M. smegmatisΔaftC and M. smegmatisΔaftC-pMV261-Mt-aftC. A. arabinofuranosyltransferase activity was determined using the synthetic ara₅ acceptor in a cell-free assay with and without EMB (1 mg ml⁻¹). The products reflective of three independent enzyme preparations and assays were re-suspended prior to scintillation counting (10%) and the remaining subjected to TLC using silica gel plates (5735 silica gel 60F254, Merck) in isopropanol/acetatic acid/water (8/1/1, v/v/v) with the reaction product X visualized by autoradiography. The TLC autoradiogram is representative of three independent experiments. B. ara₅ and ara₆ (Appelmelk et al., 2005) acceptor standards were subjected to TLC using silica gel plates (5735 silica gel 60F254, Merck) in isopropanol/acetatic acid/water (8/1/1, v/v/v) with the reaction products visualized by staining with α-naphtol followed by charring.

fuelled speculation that EmbA/B act as α(1→5) arabinofuranosyltransferases (Alderwick et al., 2005; Seidel et al., 2007a; Bhamidi et al., 2008).

In this study, we have identified MSMEG2785 (also Rv2673 and NCgl1822, which we have termed AftC, as a novel branching arabinofuranosyltransferase. More precisely, AftC catalyses the addition of α(1→3) Araf residues as shown through both in vivo and in vitro experiments, ultimately resulting in 3,5-Araf residues after further α(1→5) extension, characteristic of AG. For instance, incubation of membranes prepared from M. smegmatis with DP[14C]A and a linear α(1→5)-ara₅ neoglycolipid acceptor resulted in the synthesis of an ara₅ product. Further chemical characterization of the product by glycosyl linkage analysis established that the α(1→5)-ara₅ acceptor was extended via an EMB-resistant α(1→3) arabinofuranosyltransferase giving rise to 3-linked Araf residues and corroborated our earlier cell wall analysis of the M. smegmatisΔaftC mutant. As it is now established that only α(1→5) arabinofuranosyltransferase(s) is EMB-sensitive it can be further speculated that EmbA and EmbB function in the assembly of the linear α(1→5) arabinan segments as presented in Fig. 10, which is in accordance with previous data and the phenotype of a Cg-Emb mutant (Alderwick et al., 2005). It is clear that further studies are required to establish the precise role of EmbA and EmbB in mycobacteria.

The analysis of the M. smegmatisΔaftC mutant to date and based on the Ara : Gal ratio would suggest that the residual arabinan segment in the mutant consists of approximately five Araf residues: β-D-Araf(1→2)-α-D-Araf(1→5)-α-D-Araf(1→5)-α-D-Araf(1→5)-α-D-Araf located at three branches on the galactan chain (Besra et al., 1995; Alderwick et al., 2005). This is consistent with the recent primary structure of AG (Bhamidi et al., 2008), with a ‘non-variable’ terminal non-reducing Ara₁₇ motif, introduction of a 3,5-Araf residue distal to this non-reducing end by AftC and further extension by a linear α(1→5)Araf domain (Fig. 10). The latter appears to be variable (up to 12/13 residues). However, based on M. smegmatisΔaftC and the subsequent Ara : Gal compositional analysis a dominant Ara₂₀/Ara₂₃ motif would be consistent with recent (Bhamidi et al., 2008) and previous (Besra et al., 1995) structural data on AG and this is represented in terms of biosynthetic considerations in Fig. 10. It is also possible that AftC or a second distinct α(1→3) arabinosfuranosyltransferase (shown as AftD in Fig. 10) may be involved in late stages of AG synthesis, i.e. the non-reducing Ara₁₇ motif and is consistent with our data and the model presented in Fig. 10.

The discovery of AftC has now shed new light on the key arabinofuranosyltransferases to build an arabinan domain typical for Corynebacteriana. In this context, the genomic organization in the genomes of the Corynebacteriana sequenced is intriguing, revealing high synteny of the M. tuberculosis aftC locus to the maps of all other Mycobacterium and Corynebacterium species. The identification of new cell wall biosynthetic drug targets is of
great importance, especially with the emergence of MDR-TB. This newly discovered DPA-dependent arabinofuranosyl transferase represents, along with a straightforward in vitro enzyme assay, a promising candidate for further exploitation as a potential drug target.

**Experimental procedures**

**Bacterial strains and growth conditions**

*Corynebacterium glutamicum* ATCC 13 032 (referred to the remainder of the text as *C. glutamicum*) and *Escherichia coli* DH5αmcr were grown in Luria–Bertani broth (LB, Difco) at 30°C and 37°C respectively. The recombinant strains generated in this study were grown on complex brain–heart infusion medium (BHI, Difco), and the salt medium CGXII used for *C. glutamicum* as described (Eggeling and Reyes, 2005). Kanamycin and ampicillin were used at a concentration of 50 μg ml⁻¹. *M. smegmatis* strains were grown in tryptic soy broth (TSB; Difco), containing 0.005% Tween80 (TSBT). Solid media were made by adding 1.5% agar to the above-mentioned broths. The concentrations of antibiotics used for *M. smegmatis* were 100 μg ml⁻¹ for hygromycin and 20 μg ml⁻¹ for kanamycin. Minimal inhibitory concentrations were determined by plating cells on solid media supplemented with various concentrations of EMB, rifampicin and chloramphenicol. The minimal inhibitory concentration was defined as the first concentration of drug that would inhibit 100% of growth after 5 days of incubation (Belanger et al., 1996).

*M. tuberculosis* H37Rv DNA was obtained from the NIH Tuberculosis Research Materials and Vaccine Testing Contract at Colorado State University. All other chemicals were of reagent grade and obtained from Sigma-Aldrich.

**Construction of plasmids and strains**

Approximately 1 kb of upstream and downstream flanking sequences of *MSMEG2785* were PCR amplified from
M. smegmatis mc²155 genomic DNA using the primer pairs MS2785LL (TTTTTTTTCCATAAATTGGATCCGCTGACCGACCTCATC) and MS2785LR (TTTTTTTTCCATTTCTTGGAGCCCGAGCTTGAAGTTG), and MS2785RL (TTTTTTTTCCATAGATTGGTTCCTGCTGCTGTCCCTTGG) and MS2785RR (TTTTTTTTCCATCTTTTGGCGAACTCAGCGGCGATTCAC) respectively (all primers are given in 5′ to 3′ direction). Following restriction digestion of the primer incorporated Van91I sites, the PCR fragments were cloned into Van91I-digested p0004S to yield the knockout plasmid pDMSMEG2785 which was then packaged into the temperature-sensitive mycobacteriophage phAE159 as described previously (Bardarov et al., 2002) to yield phasmid DNA of the knockout phage phDMSMEG2785. Generation of high titre phage particles and specialized transduction were performed as described earlier (Stover et al., 1991; Bardarov et al., 2002). Deletion of MSMEG2785 in one hygromycin-resistant transductant was confirmed by Southern blot. To enable expression of MSMEG2785 and Rv2673, in the deletion mutant, these were amplified using primer pairs designed for subsequent cloning into the mycobacterial-shuttle vector pMV261 (Stover et al., 1991). All cloned fragments were verified by sequencing.

To construct the deletion vector pK19mobsacBΔaftC (NCgl 1822), cross-over PCR was applied with primer pairs AB (A, CGTTAACCGACTCTTGGATGACCGCAGCTACCATCCAAG; B, CCCATCCACTAAAACCGGCCGATCAACAAATG) and CD (C, TGTTAACCGACCTGGATGGGTGAGGGAAAGATCTT) with C. glutamicum genomic DNA as template. Both amplified products were used in a second PCR with primer pairs AD to generate a 656 bp fragment consisting of sequences adjacent to Cg-aftC, which was ligated with BamHI–HindIII-cleaved pK19mobsacB. All plasmids were confirmed by sequencing. The chromosomal deletion of Cg-aftC was performed as described previously using two rounds of positive selection (Schafer et al., 1994), and its successful deletion was verified by use of two different primer pairs.

Isolation of the mAGP complex, glycosyl composition and linkage analysis of alditol acetates by GC and GC/MS

The thawed cells were re-suspended in phosphate-buffered saline containing 2% Triton X-100 (pH 7.2), disrupted by sonication and centrifuged at 27 000 g for 1 h, washed with water, 80% (v/v) acetone in water and acetone, and finally lyophilized to yield a highly purified cell wall preparation (Besra et al., 1995; Alderwick et al., 2005). The pelleted material was extracted three times with 2% SDS in phosphate-buffered saline at 95°C for 1 h, washed with water, 80% (v/v) acetone in water and acetone, and finally lyophilized to yield a highly purified cell wall preparation (Besra et al., 1995; Alderwick et al., 2005). Cell wall or per-O-methylated cell wall preparations (Alderwick et al., 2005) were hydrolysed in 2 M TFA, reduced with NaB2H4 and the resultant alditols per-O-acetylated and examined by GC and GC/MS as described previously (Besra et al., 1995; Alderwick et al., 2005).

Extraction and analysis of cell wall-bound mycolic acids

In terms of M. smegmatis strains equivalent amounts of freeze-dried bacilli (100 mg) were processed as described...
previously (Seidel et al., 2007a), following two consecutive CHCl₃/CH₃OH/H₂O (10:10:3, v/v/v) extractions for 4 h at 50°C in the analysis of cell wall-associated lipids, and cell wall-bound MAMEs. Alternatively, *M. smegmatis* and *C. glutamicum* cultures (5 ml) were grown and metabolically labelled at mid-logarithmic phase of growth using 1 μCi ml⁻¹ [1,2-¹⁴C]acetate (50–62 mCi mmol⁻¹, GE Healthcare, Amersham Bioscience) for 4 h at either 30°C or 37°C with gentle shaking, harvested, washed and freeze-dried. Cells were then extracted by two consecutive extractions with 2 ml of CHCl₃/CH₃OH/H₂O (10:10:3, v/v/v) for 4 h at 50°C to provide cell wall-associated lipids and analysed as described previously (Seidel et al., 2007a). The crude lipid extracts were re-suspended in CHCl₃/CH₃OH (2:1) and equivalent aliquots (50 000 cpm) analysed by TLC using silica gel plates (5735 silica gel 60F254, Merck) developed in CHCl₃/CH₃OH/NH₄OH (80:20:2, v/v/v) to separate [¹⁴C]-labelled TDM and phospholipids (Mikusova et al., 1995). Lipids were visualized by autoradiography by overnight exposure of Kodak X-Omat AR film to the TLC plates to reveal labelled lipids, quantified by phosphorimaging and compared with know standards (Mikusova et al., 1995). The bound MAMEs/CMAMEs from the above de-lipidated extracts were released by the addition of 2 ml of 5% aqueous solution of tetra-butyl ammonium hydroxide followed by shaking, harvested, washed and freeze-dried. Tubes were sonicated for 15 min to re-suspend lipid linked substrates and then mixed with the remaining assay components, which included membrane protein from either *M. smegmatis*, *M. smegmatis* pMV261-Mt-aftC *M. smegmatis*DeltaAftC or *M. smegmatis*DeltaAftC pMV261-Mt-aftC (1 mg), 1 mM ATP, 1 mM NADP and in some cases EMB (0–1 mg ml⁻¹). Assays were incubated for 1 h at 37°C and quenched by the addition of 533 μl CHCl₃/CH₃OH (1:1, v/v). After mixing and centrifugation at 27 000 g for 15 min at 4°C, the supernatant was removed and dried under nitrogen. The residue was then re-suspended in 700 μl of CH₃CH₂OH/H₂O (1:1, v/v) and loaded onto a 1 ml SepPak strong anion exchange cartridge (Supelco), pre-equilibrated with CH₃CH₂OH/H₂O (1:1, v/v). The column was washed with 2 ml CH₃CH₂OH and the eluate collected, dried and partitioned between the two phases arising from a mixture of n-butanol (3 ml) and water (3 ml). The resulting organic phase was recovered following centrifugation at 3500 g and the aqueous phase again extracted twice with 3 ml of water-saturated n-butanol. The pooled extracts were back-washed twice with n-butanol-saturated water (3 ml). The n-butanol fraction was dried and re-suspended in 200 μl butanol. The extracted radiolabelled material was quantified by liquid scintillation counting using 10% of the labelled material and 5 ml of EcoScintA (National Diagnostics, Atlanta). The incorporation of [¹⁴C]Araf was determined by subtracting counts present in control assays (incubations in the absence of acceptor). The remaining labelled material was subjected to thin-layer chromatography (TLC) using either isopropanol/acetate acid/water (8:1:1, v/v/v) for the assays utilizing the Ara₅₃ acceptor or CHCl₃/CH₃OH/H₂O/NH₄OH (65:25:3:6:0.5, v/v/v/v) in the case of the Ara₅ acceptor on aluminum-backed Silica Gel 60 F254 plates (Merck, Darmstadt, Germany). Autoradiograms were obtained by exposing TLCs to X-ray film (Kodak X-Omat) for 3 days.

**Characterization of α(1→3)-arabinofuranosyltransferase activity with membranes prepared from M. smegmatis, M. smegmatisDeltaAftC and M. smegmatisDeltaAftC pMV261-Mt-aftC**

Large-scale reaction mixtures containing cold DPA (200 μg, 0.75 mM) (Lee et al., 1997) and 50 mM of the acceptor Ara₅ (both purified from *M. smegmatis*) were mixed and incubated from 15–10 mg ml⁻¹. The neoglycolipid acceptors used in this study were α-D-Araf-(1→5)-α-D-Araf-(1→5)-α-D-Araf-(1→5)-α-D-Araf-O(CH₃)₂NH₃ (Ara₅, see Supplementary material) and α-D-Araf-(1→5)-α-D-Araf-O(CH₃)₂CH₃ (Ara₃) (Lee et al., 1995; 1998). The assays (either Ara₅ or Ara₃ and DP[¹⁴C]IA (Lee et al., 1995; 1998) stored in CHCl₃/CH₃OH, 2:1, v/v) were aliquoted into 1.5 ml eppendorf tubes to a final concentration of 2 mM and 200 000 cpm (90 μM), respectively, and dried under nitrogen. The arabinofuranosyltransferase assay was carried out as described previously (Lee et al., 1997) with modifications. IgePal™ (Sigma-Aldrich) was added (0.1%, v/v) with the appropriate amount of buffer A (final volume 80 μl).
and the dried products subjected to GC (Sassaki et al., 2005) and GC/MS as described (Lee et al., 1997; Alderwick et al., 2006a).

Acknowledgements

H.L.B. is a Medical Research Council Quota Student. G.S.B. acknowledges support in the form of a Personal Research Chair from Mr James Bardrick, Royal Society Wolfson Research Merit Award, as a former Lister Institute-Jenner Research Fellow, the Medical Research Council and The Wellcome Trust (081569/Z/06/Z). A.B. is supported by a Career Development Award from the Medical Research Council. The authors would also like to thank W.R. Jacobs Jr. and Tsungda Hsu (Albert Einstein College of Medicine, New York) for the gift of plasmid p0004S.

References

Alderwick, L.J., Radmacher, E., Seidel, M., Gande, R., Hitchen, P.G., Morris, H.R., et al. (2005) Deletion of Cg-emb in corynebacterianeae leads to a novel truncated cell wall arabinogalactan, whereas inactivation of Cg-ubIA results in an arabinan-deficient mutant with a cell wall galactan core. J Biol Chem 280: 32362–32371.

Alderwick, L.J., Seidel, M., Sahm, H., Besra, G.S., and Eggeling, L. (2006a) Identification of a novel arabinofuranosyltransferase (AtA) involved in cell wall arabinan biosynthesis in Mycobacterium tuberculosis. J Biol Chem 281: 15653–15661.

Alderwick, L.J., Dover, L.G., Seidel, M., Gande, R., Sahm, H., Eggeling, L., and Besra, G.S. (2006b) Arabinan-deficient mutants of Corynebacterium glutamicum and the consequent flux in decaprenylmonophosphoryl-D-arabinose metabolism. Glycobiology 16: 1073–1081.

Amin, A.G., Guode, R., Shi, L., Zhang, J., Chatterjee, D., and Parish, T. (2008) EmbA is an essential arabinosyltransferase in Mycobacterium tuberculosis. Microbiology 154: 240–248.

Appelmelk, B.J., den Dunnen, J., Driessen, N.N., Ummels, R., Pak, M., Nigou, J., et al. (2008) The mannose cap of mycobacterial lipoarabinomannan does not dominate the Mycobacterium–host interaction. Cell Microbiol 10: 930–944.

Bardarov, S., Bardarov, S., Jr, Pavelka, M.S., Jr, Sambandamurthy, V., Jr, Larsen, M., Tufariello, J., et al. (2002) Specialized transduction: an efficient method for generating marked and unmarked targeted gene disruptions in Mycobacterium tuberculosis, M. bovis BCG and M. smegmatis. Microbiology 148: 3007–3017.

Belanger, A.E., Besra, G.S., Ford, M.E., Mikusova, K., Belisle, J.T., Brennan, P.J., and Inamine, J.M. (1996) The embAB genes of Mycobacterium avium encode an arabinosyltransferase involved in cell wall arabinan biosynthesis that is the target for the antmycobacterial drug ethambutol. Proc Natl Acad Sci USA 93: 11919–11924.

Besra, G.S., Khoo, K.H., McNeil, M.R., Dell, A., Morris, H.R., and Brennan, P.J. (1995) A new interpretation of the structure of the mycolyl-arabinogalactan complex of Mycobacterium tuberculosis as revealed through characterization of oligoglycosylalditol fragments by fast-atom bombardment mass spectrometry and 1H nuclear magnetic resonance spectroscopy. Biochemistry 34: 4257–4266.

Bhamidi, S., Scherman, M.S., Rithner, C.D., Prenni, J.E., Chatterjee, D., Khoo, K.H., and McNeil, M.R. (2008) The identification and location of succinyl residues and the characterization of the interior arabinan region allows for a model of the compete primary structure of Mycobacterium tuberculosis mycolyl arabinogalactan. J Biol Chem 283: 12992–13000.

Bhatt, A., Kremer, L., Dai, A.Z., Sacchettini, J.C., and Jacobs, W.R., Jr (2005) Conditional depletion of KasA, a key enzyme of mycobic acid biosynthesis, leads to mycobacterial cell lysis. J Bacteriol 187: 7596–7606.

Brennan, P.J., and Nikaido, H. (1995) The envelope of mycobacteria. Annu Rev Biochem 64: 29–63.

Brudno, M., Chapman, M., Gottgens, B., Batzoglou, S., and Morgenstern, B. (2003) Fast and sensitive multiple alignment of large genomic sequences. BMC Bioinformatics 4: 66.

Daffe, M., Brennan, P.J., and McNeil, M. (1990) Predominant structural features of the cell wall arabinogalactan of Mycobacterium tuberculosis as revealed through characterization of oligoglycosyl alditol fragments by gas chromatography/mass spectrometry and by 1H and 13C NMR analyses. J Biol Chem 265: 6734–6743.

Dover, L.G., Cerdeno-Tarraga, A.M., Pallen, M.J., Parkhill, J., and Besra, G.S. (2004) Comparative cell wall core biosynthesis in the mycolated pathogens, Mycobacterium tuberculosis and Corynebacterium diphtheriae. FEMS Microbiol Rev 28: 225–250.

Dye, C. (2006) Global epidemiology of tuberculosis. Lancet 367: 938–940.

Eggeling, L., and Reyes, O. (2005) Experiment. In Handbook of Corynebacterium glutamicum. Eggeling, L., and Bott, M. (eds). Boca Raton, FL: CRC Press, Taylor Francis Group, pp. 535–566.

Escuyer, V.E., Lety, M.A., Torrelles, J.B., Khoo, K.H., Tang, J.B., Rithner, C.D., et al. (2001) The role of the embA and embB gene products in the biosynthesis of the terminal hexaarabinofuranosyl motif of Mycobacterium smegmatis arabinogalactan. J Biol Chem 276: 48854–48862.

Gande, R., Gibson, K.J., Brown, A.K., Krumbach, K., Dover, L.G., Sahm, H., et al. (2004) Acyl-CoA carboxylases (accD2 and accD3), together with a unique polyketide synthase (Cg-pks), are key to mycolic acid biosynthesis in Corynebacterianeae such as Corynebacterium glutamicum and Mycobacterium tuberculosis. J Biol Chem 279: 44847–44857.

Guvenen, Z.T., and McCarter, L.L. (2003) Multiple regulators control capsular polysaccharide production in Vibrio parahaemolyticus. J Bacteriol 185: 5431–5441.

Kaye, K., and Frieden, T.R. (1996) Tuberculosis control: the relevance of classic principles in an era of acquired immunodeficiency syndrome and multidrug resistance. Epidemiol Rev 18: 52–63.

Lee, R.E., Mikusova, K., Brennan, P.J., and Besra, G.S. (1995) Synthesis of the arabino-neuraminic acid β-o-
arabinofuranosyl-1-monophosphoryldecaprenol, development of a basic arabinosyl-transferase assay, and identification of ethambutol as an arabinosyltransferase inhibitor. *J Am Chem Soc* **117**: 11829–11832.

Lee, R.E., Brennan, P.J., and Besra, G.S. (1997) Mycobacterial arabinan biosynthesis: the use of synthetic arabinoside acceptors in the development of an arabinosyl transfer assay. *Glycobiology* **7**: 1121–1128.

Lee, R.E., Brennan, P.J., and Besra, G.S. (1998) Synthesis of β-D-arabinofuranosyl-1-monophosphoryl polypropenol: examination of their function as mycobacterial arabinosyl transferase donors. *Bioorg Med Chem Lett* **8**: 951–954.

Liu, J., and Mushegian, A. (2003) Three monophylectic superfamilies account for the majority of the known glycosyltransferases. *Protein Sci* **12**: 1418–1431.

McNeil, M., Daffe, M., and Brennan, P.J. (1990) Evidence for the nature of the link between the arabinogalactan and peptidoglycan of mycobacterial cell walls. *J Biol Chem* **265**: 18200–18206.

McNeil, M., Daffe, M., and Brennan, P.J. (1991) Location of the mycolyl ester substituents in the cell walls of mycobacteria. *J Biol Chem* **266**: 13217–13223.

Mikusova, K., Slayden, R.A., Besra, G.S., and Brennan, P.J. (1995) Biogenesis of the mycobacterial cell wall and the site of action of ethambutol. *Antimicrob Agents Chemother* **39**: 2484–2489.

Mills, J.A., Motichka, K., Jucker, M., Wu, H.P., Uhlk, B.C., Stern, R.J., et al. (2004) Inactivation of the mycobacterial rhamnosyltransferase, which is needed for the formation of the arabinogalactan-peptidoglycan linker, leads to irreversible loss of viability. *J Biol Chem* **279**: 43540–43546.

Minnikin, D.E. (1982) Lipids: complex lipids, their chemistry, biosynthesis and roles. In *The Biology of the Mycobacteria*. Ratledge, C., and Stanford, J. (eds). London: Academic Press, pp. 95–184.

Mishra, A.K., Alderwick, L.J., Rittmann, D., Tatituri, R.V., Nigou, J., Gilleron, M., et al. (2007) Identification of an α(1→6) mannopyranosyltransferase (MptA), involved in *Corynebacterium glutamicum* lipomannan biosynthesis, and identification of its orthologue in *Mycobacterium tuberculosis*. *Mol Microbiol* **65**: 1503–1517.

Mishra, A.K., Alderwick, L.J., Rittmann, D., Wang, C., Bhatt, A., Jacobs, W.R., Jr, et al. (2008) Identification of a novel α(1→6) mannopyranosyltransferase (MptB) from *Corynebacterium glutamicum* by deletion of a conserved gene, NCgl1505, affords a lipomannann- and lipoolarabinomann-deficient mutant. *Mol Microbiol* **68**: 1595–1613.

Pan, F., Jackson, M., Ma, Y., and McNeil, M. (2001) Cell wall core galactofuran synthesis is essential for growth of mycobacteria. *J Bacteriol* **183**: 3991–3998.

Paolo, W.F., Jr and Nosanchuk, J.D. (2004) Tuberculosis in New York city: recent lessons and a look ahead. *Lancet Infect Dis* **4**: 287–293.

Parish, T., Roberts, G., Laval, F., Schaeffer, M., Daffe, M., and Duncan, K. (2007) Functional complementation of the essential gene fabG1 of *Mycobacterium tuberculosis* by *Mycobacterium smegmatis* fabG but not *Escherichia coli* fabG. *J Bacteriol* **189**: 3721–3728.

Portevin, D., De Sousa-D’Auria, C., Houssin, C., Grimaldi, C., Chami, M., Daffe, M., and Guilhot, C. (2004) A polyketide synthase catalyzes the last condensation step of mycolic acid biosynthesis in mycobacteria and related organisms. *Proc Natl Acad Sci USA* **101**: 314–319.

Radmacher, E., Stansen, K.C., Besra, G.S., Alderwick, L.J., Maughan, W.N., Hollweg, G., et al. (2005) Ethambutol, a cell wall inhibitor of *Mycobacterium tuberculosis*, elicits 1-glutamate efflux of *Corynebacterium glutamicum*. *Microbiology* **151**: 1359–1368.

Sassaki, G.L., Iacaimini, M., and Gorin, P.A.J. (2005) Methylation-GC-MS analysis of arabinofuranose-and galactofuranose-containing structures: rapid synthesis of partially O-methylated alditol acetates. *An Acad Bras Cienc* **77**: 223–234.

Scherer, A., Tauch, A., Jager, W., Kainlowski, J., Thierbach, G., and Puhler, A. (1994) Small mobilizable multi-purpose cloning vectors derived from the *Escherichia coli* plasmids pK18 and pK19: selection of defined deletions in the chromosome of *Corynebacterium glutamicum*. *Gene* **145**: 69–73.

Seidel, M., Alderwick, L.J., Birch, H.L., Sahm, H., Eggeiling, L., and Besra, G.S. (2007a) Identification of a novel arabinofuranosyltransferase AftB involved in a terminal step of cell wall arabinan biosynthesis in *Corynebacteriaceae*, such as *Corynebacterium glutamicum* and *Mycobacterium tuberculosis*. *J Biol Chem* **282**: 14729–14740.

Seidel, M., Alderwick, L.J., Sahm, H., Besra, G.S., and Eggeeling, L. (2007b) Topology and mutational analysis of the single Emb arabinofuranosyltransferase of *Corynebacterium glutamicum* as a model of Emb proteins of *Mycobacterium tuberculosis*. *Glycobiology* **17**: 210–219.

Shah, N.S., Wright, A., Bai, G.H., Barrera, L., Boulaibal, F., Martin-Casabona, N., et al. (2007) Worldwide emergence of extensively drug-resistant tuberculosis. *Emerg Infect Dis* **13**: 380–387.

Stover, C.K., de la Cruz, V.F., Fuerst, T.R., Burlein, J.E., Benson, L.A., Bennett, L.T., et al. (1991) New use of BCG for recombinant vaccines. *Nature* **351**: 456–460.

Takayama, K., and Kilburn, J.O. (1989) Inhibition of synthesis of arabinogalactan by ethambutol in *Mycobacterium smegmatis*. *Antimicrob Agents Chemother* **33**: 1493–1499.

Talenti, A., Philipp, W.J., Sreevatsan, S., Bernasconi, C., Stockbauer, K.E., Wiebes, B., et al. (1997) The emb operon, a gene cluster of *Mycobacterium tuberculosis* involved in resistance to ethambutol. *Nat Med* **3**: 567–570.

Vlicheze, C., Morbidoni, H.R., Weisbord, T.R., Imamoto, H., Kuo, M., Sacchettini, J.C., and Jacobs, W.R. Jr (2000) Inactivation of the inhA-encoded fatty acid synthase II (FASII) enoyl-acyl carrier protein reductase induces accumulation of the FASII end products and cell lysis of *Mycobacterium smegmatis*. *J Bacteriol* **182**: 4059–4067.

Walucka, B.A., McNeil, M.R., de Hoffmann, E., Chojnacki, T., and Brennan, P.J. (1994) Recognition of the lipid intermediate for arabinogalactan/arabinomannan biosynthesis and its relation to the mode of action of ethambutol on mycobacteria. *J Biol Chem* **269**: 23328–23335.

Zhang, N., Torrelles, J.B., McNeil, M.R., Escuyer, V.E., Khoo, K.H., Brennan, P.J., and Chatterjee, D. (2003) The Emb proteins of mycobacteria direct arabinosylation of lipoolarabinomannan and arabinogalactan via an N-terminal recognition region and a C-terminal synthetic region. *Mol Microbiol* **50**: 69–76.
Supplementary material

This material is available as part of the online article from: http://www.blackwell-synergy.com/doi/abs/10.1111/j.1365-2958.2008.06354.x
(This link will take you to the article abstract).

Please note: Blackwell Publishing is not responsible for the content or functionality of any supplementary materials supplied by the authors. Any queries (other than missing material) should be directed to the corresponding author for the article.